Bafna Pharmaceuticals Ltd
Bafna Pharmaceuticals Ltd (BAFNAPH) last reported results for the quarter ended Sep 2019, with sales of ₹11.57 crore and net profit of ₹-0.59 crore. The stock last traded at ₹401, a market capitalisation of ₹948 crore. Over the past 52 weeks the stock has ranged between ₹94.8 and ₹401. Figures are as of 6 Oct 2026 and are not real time.
Bafna Pharmaceuticals Ltd share price and key metrics
- Current price
- ₹401
- Market cap
- ₹948 cr
- Book value
- ₹216
- ROE
- -6.18%
- ROCE
- -3.00%
- Dividend yield
- 0.00%
- 52w high / low
- 401/94.8
Metrics as of 6 Oct 2026. Not real time.
Track Bafna Pharmaceuticals Ltd
Cruxal reads every Bafna Pharmaceuticals Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Bafna Pharmaceuticals Ltd growth and returns
- 10 Years
- %
- 5 Years
- -15%
- 3 Years
- -13%
- TTM
- -3%
- 10 Years
- %
- 5 Years
- 14%
- 3 Years
- 24%
- TTM
- 89%
- 10 Years
- 28%
- 5 Years
- 24%
- 3 Years
- 61%
- 1 Year
- 124%
- 10 Years
- %
- 5 Years
- -45%
- 3 Years
- -64%
- Last Year
- -6%
Bafna Pharmaceuticals Ltd quarterly results
| ₹ crore | Jun 2018 | Sep 2018 | Jun 2019 | Sep 2019 |
|---|---|---|---|---|
| Sales | 11.95 | 8.84 | 6.85 | 11.57 |
| Expenses | 13.77 | 8.66 | 9.71 | 11.95 |
| Operating profit | -1.82 | 0.18 | -2.86 | -0.38 |
| OPM % | -15.23% | 2.04% | -41.75% | -3.28% |
| Other income | 0.09 | -0.03 | 0.3 | 0.59 |
| Interest | 0.83 | 0.62 | 0.13 | 0.04 |
| Depreciation | 1 | 0.75 | 1.02 | 0.72 |
| Profit before tax | -3.56 | -1.22 | -3.71 | -0.55 |
| Tax % | -1.12% | 4.10% | -42.59% | 7.27% |
| Net profit | -3.52 | -1.28 | -2.13 | -0.59 |
| EPS (₹) | -1.49 | -0.54 | -0.90 | -2.49 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Bafna Pharmaceuticals Ltd annual results
| ₹ crore | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 129 | 175 | 185 | 97 | 85 | 65 | 46 | 44 | 42 |
| Operating profit | 19 | 22 | 23 | -18 | 1 | -6 | -35 | -13 | 1 |
| OPM % | 15% | 13% | 12% | -18% | 0.6% | -9% | -77% | -30% | 2.9% |
| Net profit | 2 | 4 | 1 | 6 | -15 | -19 | -17 | -18 | -24 |
| EPS (₹) | 1.00 | 2.12 | 0.75 | 3.31 | -7.52 | -10.23 | -7.08 | -7.98 | -104.54 |
TTM is the trailing twelve months to the most recent quarter.
Bafna Pharmaceuticals Ltd balance sheet
| ₹ crore | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 |
|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 18 | 19 | 19 | 19 | 19 | 19 | 24 | 24 | 2 |
| Reserves | 45 | 49 | 50 | 53 | 39 | 24 | 14 | -5 | 49 |
| Borrowings | 85 | 100 | 108 | 69 | 80 | 82 | 47 | 46 | 3 |
| Other liabilities | 70 | 93 | 59 | 59 | 54 | 53 | 54 | 54 | 17 |
| Total liabilities | 219 | 261 | 236 | 200 | 193 | 178 | 138 | 119 | 71 |
| Fixed assets | 76 | 73 | 69 | 55 | 53 | 49 | 45 | 37 | 35 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 17 | 17 | 17 | 0 | 0 | 0 |
| Other assets | 143 | 188 | 167 | 128 | 123 | 113 | 93 | 82 | 36 |
| Total assets | 219 | 261 | 236 | 200 | 193 | 178 | 138 | 119 | 71 |
As reported by the company. Total assets equal total liabilities by construction.
Bafna Pharmaceuticals Ltd cash flow
| ₹ crore | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 29 | 37 | 2 | 11 | 1 | -1 | -7 | -2 | -34 |
| Cash from investing | -38 | -6 | -7 | 60 | -0 | -5 | 38 | 15 | 33 |
| Cash from financing | -1 | -12 | -13 | -71 | -1 | 6 | -31 | -14 | 7 |
| Net cash flow | -9 | 19 | -18 | -0 | -0 | -0 | 0 | -0 | 6 |
| Free cash flow | -1 | 34 | -0 | 44 | -1 | -1 | 40 | 3 | -36 |
| CFO / operating profit | 161% | 167% | 9% | -73% | 175% | 16% | 20% | 14% | -2,812% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Bafna Pharmaceuticals Ltd operating ratios
| Per year | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 |
|---|---|---|---|---|---|---|---|---|---|
| ROCE % | — | 11% | 9% | -12% | -2% | -7% | -36% | -22% | -3% |
| Debtor days | 237 | 191 | 193 | 335 | 292 | 303 | 195 | 208 | 52 |
| Inventory days | 93 | 63 | 77 | 72 | 90 | 118 | 102 | 122 | 208 |
| Days payable | 227 | 223 | 118 | 189 | 208 | 168 | 273 | 519 | 229 |
| Cash conversion cycle | 103 | 30 | 152 | 218 | 174 | 253 | 24 | -190 | 31 |
| Working capital days | 35 | -5 | 36 | 50 | 106 | -39 | -113 | -210 | 90 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Bafna Pharmaceuticals Ltd shareholding pattern
Promoters held 75.00% at Jun 2026, broadly unchanged since Jun 2025. FIIs 9.34%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 88.29% | 88.29% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% |
| FIIs | 0.00% | 0.00% | 8.53% | 9.34% | 9.34% | 9.34% | 9.34% | 9.34% |
| Public | 11.70% | 11.70% | 16.47% | 15.66% | 15.66% | 15.66% | 15.66% | 15.66% |
| No. of shareholders | 7,295 | 7,214 | 7,142 | 7,283 | 7,572 | 7,119 | 6,928 | 7,062 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Bafna Pharmaceuticals Ltd corporate filings
- Intimation for Closure of Trading WindowInsider Trading / SASTlow impact
- Bafna Pharmaceuticals Limited announces successful conclusion of 31st Annual General MeetingAGM/EGMlow impact
Cruxal's analysis: Bafna Pharmaceuticals Limited has successfully concluded its 31st Annual General Meeting…
Read the full analysis - Bafna Pharmaceuticals Limited concludes 31st Annual General Meeting with routine agenda itemsAGM/EGMlow impact
Cruxal's analysis: Bafna Pharmaceuticals Limited has successfully concluded its 31st Annual General Meeting…
Read the full analysis - Bafna Pharmaceuticals Ltd announces 31st Annual General Meeting dateCompany Updatelow impact
Cruxal's analysis: Bafna Pharmaceuticals has published the notice for its 31st Annual General Meeting in…
Read the full analysis - Bafna Pharmaceuticals Reports Strong FY26 Financial Performance with 167% Net Profit GrowthAGM/EGMhigh impact
Cruxal's analysis: Bafna Pharmaceuticals Limited has released its Annual Report for FY 2025-26, showcasing…
Read the full analysis - Bafna Pharmaceuticals Ltd files Annual Report for FY 2025-2026Otherslow impact
Cruxal's analysis: Bafna Pharmaceuticals has submitted its Annual Report for the financial year 2025-2026 as…
Read the full analysis - Bafna Pharmaceuticals Reports Continued Operating Losses for Quarter Ended June 30, 2026Company Updatelow impact
Cruxal's analysis: Bafna Pharmaceuticals Limited has released its unaudited financial results for the…
Read the full analysis - Bafna Pharmaceuticals Ltd announces book closure and cut-off dates for 31st Annual General MeetingCorp. Actionlow impact
Cruxal's analysis: Bafna Pharmaceuticals has issued an intimation regarding the book closure and cut-off…
Read the full analysis - Bafna Pharmaceuticals Limited schedules 31st Annual General Meeting for September 11, 2026AGM/EGMlow impact
Cruxal's analysis: Bafna Pharmaceuticals Limited has announced that its 31st Annual General Meeting will be…
Read the full analysis - Bafna Pharmaceuticals reports significant Q1 FY27 earnings contraction with net profit falling to INR 7.51 lakhBoard Meetinghigh impact
Cruxal's analysis: Bafna Pharmaceuticals Limited reported a sharp decline in financial performance for the…
Read the full analysis - Bafna Pharmaceuticals Limited schedules Board Meeting for August 11, 2026, to approve Q1 FY27 financial resultsBoard Meetinglow impact
Cruxal's analysis: Bafna Pharmaceuticals Limited has issued a formal intimation regarding a Board of…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.